Viatris (VTRS) Nyanmɛn Kpɛn
Viatris
AI bɛ́nɛ́nɛ́: VTRS
AI bɛ sɔhɛn sɛn na ɛbɛ yɛ a ɛwɔ nna a ɛdi akyi, nnwɔtwe no awieeɛ ne bosome no awieeɛ. Nsakraeɛ no yɛ nea wɔhwɛ firi sika a ɛwɔ hɔ seesei. Eyinom yɛ nkyɛmu nhyehyɛeɛ, ɛnyɛ nkyɛmu a wɔde bɛyɛ adwuma.
Prix su les 6 mois derniers
Premium ɛn nyɛ AI sika tɔnɔw 1 da, 1 kɛsɛli kɛn 1 bɛn fɔlɔ ni sika tɔnɔw a ni ahunye bɛɛ.
Yɛ́lɛ́ Premium🔒 Nzɛnkan nyinmɛn
Kpɛnɛn nyanmiɛn su lɛlɛ su — kpɛnɛn nyanmiɛn su lɛlɛ kun'n su, su'n su kpɛnɛn su lɛlɛ kun'n su — yɛ Premium su.
Yɛ́lɛ́ PremiumNyanmiɛn nɛnɛn
On November 16, 2020, Viatris Inc. was formed through the successful merger of Mylan N.V. and Pfizer’s Upjohn business unit. Leveraging the heritage of these two complementary businesses, Viatris possesses scientific, manufacturing, and logistics infrastructure, as well as significant expertise in regulatory, medical, and commercial matters, enabling it to provide patients with quality medicines in more than 165 countries.
